ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1979

Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis

Jie Wei1, david Hunter2, Nancy Lane3, Jing Wu4, Chao Zeng5, Guanghua Lei5 and Yuqing Zhang6, 1Health Management Center, Xiangya Hospital Central South University, Changsha, China, 2Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, 3University of California, Hillsborough, CA, 4Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, 5Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, 6Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Epidemiology, longitudinal studies, Mortality, obesity, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1977–1995) Osteoarthritis – Clinical Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The current international guidelines recommend weight loss for pain relief and functional improvement in overweight or obese patients with knee or hip osteoarthritis; however, there is a paucity of data on the relation of weight loss to all-cause mortality among patients with osteoarthritis. We aimed to examine the relation of the rate of weight loss induced by anti-obesity medications over 1-year to all-cause mortality among overweight/obese patients with knee or hip osteoarthritis.

Methods: Using IQVIA Medical Research Database in the United Kingdom, we identified overweight/obese people aged 40 years or older with knee or hip osteoarthritis. We emulated analyses of a hypothetical target trial using a “cloning, censoring, and weighting” approach to assess the effect of slow-to-moderate (2-10%) or fast (≥10%) weight loss induced by the initiation of anti-obesity medications (i.e., orlistat, sibutramine, and rimonabant) within 1-year on all-cause mortality and several secondary outcomes (i.e., incident hypertension, type 2 diabetes, venous thromboembolism, cardiovascular disease, and any cancer) over 5-year follow-up, respectively (Figure 1).

Results: Among 6,524 participants initiating anti-obesity medications, the 5-year all-cause mortality was 5.3%, 4.0%, and 5.4% for “weight gain/stable”, “slow-to-moderate weight loss” and “fast weight loss” arms, respectively. Compared with the “weight gain/stable” arm, hazard ratios (HRs) of all-cause mortality were 0.72 (95% confidence interval [CI]: 0.56-0.92) for the “slow-to-moderate weight loss” arm and 0.99 (95%CI: 0.67-1.44) for the “fast weight loss” arm, respectively. In addition, we found dose-response protective effects of weight loss on incident hypertension, type 2 diabetes, and venous thromboembolism. However, a slightly higher risk of cardiovascular disease, albeit non-statistically significant, was observed in the “fast rate of weight loss” arm compared with the “weight gain/stable” arm (HR=1.20, 95%CI: 0.81-1.78). No apparent difference in the risk of cancer was observed between the “fast rate of weight loss” arm and the “weight gain/stable” arm (HR=1.04, 95%CI: 0.74-1.45) (Table 1).

Conclusion: In this population-based study, a slow-to-moderate, but not fast, rate of weight loss induced by anti-obesity medications within 1-year is associated with a lower risk of all-cause mortality in overweight/obese people with knee or hip osteoarthritis. Our findings that gradual weight loss by anti-obesity medications lower all-cause mortality, if confirmed by future studies, could guide policy-making, and improve the well-being of overweight/obese patients with knee or hip OA.

Supporting image 1

Figure 1. Study design of a hypothetical randomized controlled trial (“target trial”) on which we modeled our observational data analysis (A); Cloning and censoring in five hypothetical patients (B). Patient A lost ≥ 10% weight within one year after anti-obesity medications initiation. At time zero, 3 copies of the patient are made and they are randomly allocated to three groups. Patient A lost ≥ 10% weight within one year after anti-obesity medications initiation. The copy assigned to the “fast rate of weight loss” group is adhered with his/her assignment and will not be censored. However, the other two copies assigned to the “weight gain/stable” group and “slow-to-moderate rate of weight loss” group are violated with their assignment, and thus be censored at the time.

Supporting image 2

Table 1. Relations of weight reduction induced by anti-obesity medications within 1-year to all-cause mortality, incident hypertension, T2DM, VTE, CVD and cancer in overweight or obese knee or hip OA patients


Disclosures: J. Wei: None; d. Hunter: None; N. Lane: None; J. Wu: None; C. Zeng: None; G. Lei: None; Y. Zhang: None.

To cite this abstract in AMA style:

Wei J, Hunter d, Lane N, Wu J, Zeng C, Lei G, Zhang Y. Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/weight-loss-induced-by-anti-obesity-medications-and-all-cause-mortality-among-patients-with-knee-or-hip-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/weight-loss-induced-by-anti-obesity-medications-and-all-cause-mortality-among-patients-with-knee-or-hip-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology